Haematologica (Jul 2007)

FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma

  • Zdravko Mitroviç,
  • Igor Aurer,
  • Ivo Radman,
  • Radmila Ajdukoviç,
  • Jadranka Sertiç,
  • Boris Labar

DOI
https://doi.org/10.3324/haematol.10327
Journal volume & issue
Vol. 92, no. 7

Abstract

Read online

We investigated the association of FcγRIIIa and FcγRIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcγRIIIa and FcγRIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via FcγRIIIa and FcγRIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.